Abstract Treatment of neuropathic pain remains inadequate despite the elucidation of
multiple pathophysiological mechanisms and the development of promising therapeutic …

Fabry disease is a monogenic disease characterized by a deficiency or loss of the α-
galactosidase A (GLA). The resulting impairment in lysosomal GLA enzymatic activity leads …

Fabry disease is generally considered to be the second most prevalent lysosomal storage
disorder, after Gaucher disease, with an estimated incidence ranging between 1: 40,000 …

Fabry disease (FD) is a progressive multisystemic lysosomal storage disease. Early
diagnosis by newborn screening (NBS) may allow for timely treatment, thus preventing …

Anderson-Fabry disease (AFD) is an X-linked lysosomal storage disorder caused by
deficient activity of the enzyme alpha-galactosidase. While AFD is recognized as a …

Surface-enhanced Raman scattering (SERS) has been extensively applied to detect
complex analytes due to its ability to enhance the fingerprint signals of molecules around …

Fabry disease is an X-linked progressive lysosomal disorder, due to α-galactosidase A
deficiency. Patients with a classic phenotype usually present in childhood as a multisystemic …

Plasmalogens (vinyl‐ether phospholipids) are an emergent class of lipid drugs against
various diseases involving neuro‐inflammation, oxidative stress, mitochondrial dysfunction …

Fabry Disease (FD) is a rare lysosomal storage disorder caused by mutations in the GLA
gene on the X chromosome, leading to a deficiency in α-galactosidase A (AGAL) enzyme …

Inherited renal diseases represent 20% of the causes of end-stage renal diseases. Fabry
disease, an X-linked lysosomal storage disorder, results from α-galactosidase A deficient or …